checkAd

    MYRIAD +++ Eine interessante Aktie im Schatten der großen und gepuschten+++ - 500 Beiträge pro Seite

    eröffnet am 27.06.00 20:34:51 von
    neuester Beitrag 24.08.00 00:25:04 von
    Beiträge: 28
    ID: 169.063
    Aufrufe heute: 0
    Gesamt: 2.134
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 27.06.00 20:34:51
      Beitrag Nr. 1 ()
      Hi Leute,
      ich möchte ein Unternehmen vorstellen, das hier trotz ausgezeichneter Kursentwicklung bisher eher unbeachtet geblieben ist.

      Myriad Genetics Inc. (MYGN, 897518) ist nach eigenen Angaben führend in der Identifikation von bestimmten, in Korrelation mit Krankheiten stehenden Genen. Bereits gefunden seien die verantwortlichen Gene für Brust-, Eierstock-, Gehirn- und Hautkrebs sowie drei weitere, nicht näher bezeichneten Krebsarten. Weit fortgeschritten ist auch die Erforschung von Prostata-, Lungen- und Blutkrebs. Darüber hinaus forscht im Myriad nach den Genen für Asthma, Osteoporose, Demenz und Depressionen und hat auch hier erste Erfolge vorzuweisen. Eine vollständige Übersicht findet Ihr unter http://www.myriad.com/invg.html. Die Markteinführung von Medikamenten auf Basis dieser Forschungsergebnisse wird jedoch noch einige Jahre dauern.
      Bereits zugelassen sind zwei Tests auf Genbasis, die die frühzeitige Erkennung von Prostata- und Brustkrebs ermöglichen und weltweit als Standard anerkannt sind. Der Umsatz mit Gentests wächst zur Zeit mit 25% im Quartal.
      Myriads Ass im Ärmel ist vielleicht die sogenannte ProNet-Technologie, die zur Identifikation von Proteinen eingesetzt wird. Diese Technologie ermöglicht, die Funktionsweisen von Proteinen in Krankheitsprozeßen zu verstehen und weitere beteiligte Proteine und sogar Gene zu ermitteln. Dadurch können Hinweise auf potentiell interessante Gene gewonnen werden. Die ProNet-Technologie ist laut Myriad außerdem vielseitig einsetzbar: "ProNet has the ability to find all classes of proteins- intracellular, secreted and membrane-associated. The system is equally applicable to human, microbial, veterinary, and agricultural research." Im Vergleich zu bisherigen Analyseverfahren bietet ProNet einen 1000mal höhere Analysegeschwindigkeit bei 20mal genaueren Ergebnissen. Die ProNet-Technologie ist auch Bestandteil der meisten strategischen Allianzen, die Myriad bislang mit Bayer, Eli Lilly, Hitachi, NADII, Novartis, Pharmacia, Roche, Schering und Schering-Plough eingegangen ist. Myriad beziffert den "Total Potential Value of Collaborations" mit "$393 million plus royalties and profit sharing".
      Die Marktkapitalisierung beträgt zur Zeit 1,4 B $.



      Ich bin nicht in Myriad investiert, erwäge aber ernsthaft noch einzusteigen.

      Gruß, ml
      Avatar
      schrieb am 27.06.00 21:02:54
      Beitrag Nr. 2 ()
      Hier ein Vergleich

      MLNM market cap = $ 10,667,386,125
      HGSI market cap = $ 6,119,330,000
      CRA market cap = $ 5,492,340,000
      INCY market cap = $ 2,424,855,000
      MYGN market cap = $ 1,370,299,000

      Ist dieser Abschlag in der Höhe gerechtfertigt?


      Achtung: MYGN ist morgen auch in F.´s Magazin, also vorischt vor Aufschlag in D, fals einer kaufen will!
      Avatar
      schrieb am 27.06.00 21:25:28
      Beitrag Nr. 3 ()


      Na, ist das nichts, was MYGN aufzuweisen hat:
      Da sage ich nur: erstklassig postioniert!

      Strategic Alliances

      Bayer Asthma, Obesity, Osteoporosis
      ProNet - Depression and Dementia
      $137 million plus royalties
      Eli Lilly BRCA1 gene discovery $4 million plus royalties
      Hitachi ProNet $26 million plus royalties
      NADII Genomic Sequencing - Crop plants $34 million plus 50% profit sharing
      Novartis Cardiovascular Disease $60 million plus royalties
      Pharmacia ProNet - Three disease pathways $28 million plus royalties
      Roche ProNet $13.5 milion plus royalties
      Schering AG ProNet - Cancer and Cardiovascular Disease $56 million plus 50% profit sharing
      Schering-Plough Cancer $60 million plus royalties
      Total Potential Value of Collaborations $393 million plus royalties
      and profit sharing


      Hinweis: royalties sind Umsatzbeteiligungen, die MYGN erhält, wenn die von MYGN identifizierten Gene zu Pr#rparaten und letztlich zuUmsätzen führen!

      Hier noch die Pipeline im Bild:

      Sicherlich gibts noch keine klinischen Studien, aber wie ist das denn bei CRA?
      Avatar
      schrieb am 27.06.00 21:39:49
      Beitrag Nr. 4 ()
      mal wieder keiner interessiert?
      Avatar
      schrieb am 27.06.00 22:17:58
      Beitrag Nr. 5 ()
      HI LEUTE

      ICH BIN SCHON LAENGER IN MYRIAD INVESTIERT. SOLLTE DER WIDERSTAND BEI CA 150 DOLLAR GEKNACKT WERDEN, WIRD DIESE AKTIE REGELRECHT EXPLODIEREN. SIEHE CHART!

      VIEL GLUECK

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 27.06.00 23:46:17
      Beitrag Nr. 6 ()
      hallo IWA Japan,
      schön daß wenigstens Du Dich für meinen Thread (mein erster! Ich beobachte das ganze hier schon einige Zeit und habe nun beschlossen, ab und an ein wenig mitzumischen) interessierst. Wie ich sehe, bist Du ja gleich voll im Bilde. Wie lange beobachtest Du MYGN schon?
      Ich liege jetzt schon eine ganze Weile auf der Lauer, habe aber bei 90$ den Aufsprung verpaßt, da ging alles plötzlich ziemlich schnell (siehe Chart). Aber ich bin auch auf dem gegenwärtigen Niveau immer noch interessiert. Habe zwar so gut wie kein Cash mehr, aber ich könnte die Hälfte meiner MEDX verkaufen, die ich ohnehin übergewichtet habe, worüber ich im Moment nicht mehr ganz glücklich bin...
      Jedenfalls ist ein guter Freund von mir heute in MYGN rein, und ich glaube, ich sollte das auch noch tun. Wie Du durch den Vergleich oben schon angedeutet hast, spricht die Marktkapitalisierung in anbetracht der bisherigen Forschungserfolge einfach für sich.

      @OLLIF
      Seit wann bist Du drin und wie bist Du auf Myriad aufmerksam geworden?
      Avatar
      schrieb am 27.06.00 23:54:07
      Beitrag Nr. 7 ()
      Hat dich etwa dein Spirituosen-Kumpane Montana auf Börse gebracht.

      Dachte, du hättest viellecht die ID gewechselt.

      Habe MYGN schon etwas länger auf der Watchlist.

      Montana hat den Wert schon mal erwähnt, ich anschließend auch ein paar MAl, habe aber nie etwas dazu geshrieben, deshalb vielen Dank dafür!

      Ich garaniere dir, dass du morgen einige Rezessionen für diesen interessanten Wert bekommst. Grund: Morgen ist MYGN im AKtionär.

      Bin mal gespannt, welchen Aufschlag morgen die LEmminge bezahlen müssen inDEutschland, die sofort wg. der Heftempfehlung kaufen!
      Avatar
      schrieb am 28.06.00 00:53:55
      Beitrag Nr. 8 ()
      Auf die Biotechs hat er mich gebracht (Danke nochmal!). Die Börse interessiert mich schon länger, mal mehr und mal weniger: Mit 14 den ersten Optionsschein, mit 15 den ersten Totalverlust (Fokker). Hoffentlich auch der letzte. So, für heute erst mal Schluß, da kommt gerade einer mit `nem Six-Pack! :)
      Avatar
      schrieb am 28.06.00 01:31:23
      Beitrag Nr. 9 ()
      na dann ist ja gut, denn ich habe mir heute gegen viertel vor acht noch hektisch ein paar myriad billigst (140) ins depot gelegt.

      schade, daß man auf einen solchen wert nicht früher aufmerksam geworden ist (zumindest ich). ist eine schwäche von mir,
      daß ich zu sehr auf meine werte fixiert bin und nicht genug auf andere werte schaue...

      sollten wir hier morgen aufgelder von mehr als 15% sehen, werde ich aber verkaufen und nach börseneröffnung in usa wieder
      reingehen.

      ach übrigens, iwa: heute ist vom UN-hiv-bekämpfungsprogramm in genf (?) eine statistik über todesfälle, neu-infizierungen usw.
      veröffentlicht worden:

      ich habe die zahlen nicht mehr komplett im kopf, aber die wichtigsten kriege ich noch hin:

      weltweit sind ca. 35 mio menschen mit hiv infiziert, davon über 25 mio in schwarzafrika. 1999 haben sich ca. 5,5 mio menschen
      neu infiziert, davon wiederum in afrika ca. 4,2 mio. zum vergleich: in deutschland waren es "nur" 37 tsd, mit stark rückläufiger
      tendenz (wie überhaupt in europa und nordamerika !).

      will wirklich nicht rechthaberisch sein, aber aids ist zum ganz ganz großen teil ein problem der dritten welt und nicht der reichen
      industrieländer! meine these aus dem hiv-thread wurde durch den bericht bestätigt. ich bleibe daher dabei, daß meiner meinung
      nach im krebs-sektor wesentlich (!) mehr geld zu verdienen ist, als im hiv-sektor - die am schlimmsten betroffenen länder
      afrikas sind gleichzeitig die ärmsten, die für zinstilgungen ca. das doppelte ausgeben, wie für ihr gesundheitssystem...

      so, erst mal bis dann, werde jetzt mit m. lynched, der faulen kanalratte, "haschisch spritzen und stromgitarre spielen, wie meine
      oma immer sagt"...

      so long,

      Mr. Montana

      so long
      Avatar
      schrieb am 28.06.00 11:19:35
      Beitrag Nr. 10 ()
      nun gut, aber jedbefalls ist in Nordamerika ein genügend großer Markt ,wie ich ja in andrm Threasd zeigte, vorhanden. udem VRTX etwa ist ja nicht nur AIDS, sondern vile mehr, dasselbe gilt für BCHE und GILD
      Avatar
      schrieb am 06.07.00 21:33:23
      Beitrag Nr. 11 ()
      O.K., wenn sich mit HIV sowieso kein Geld verdienen läßt, kümmern wir uns lieber wieder um Krebs... und Myriad.


      Der Pharmakonzern AstraZeneca hat am 30. Juni von der FDA die Zulassung für Tamoxifen erhalten, das die meisten Arten von
      Brustkrebs am Wachstum hindert, indem die Östrogenzufuhr abgeschnitten wird. Tamoxifen ist besonders zur Behandlung einer
      leichteren, noch gut behandelbaren Brustkrebsform geeignet, bei der zunächst nur die Milchdrüsen betroffen sind, aber auch gravierendere
      Formen entstehen können. Auch Eli Lilly arbeitet an einem ähnlich wirkenden Medikament.

      Allein in den USA werden jedes Jahr mehr als 180.000 neue Brustkrebsdiagnosen gestellt.

      Was das mit Myriad zu tun hat?

      Wie ich bereits erwähnt habe, ist MYGN der weltweit einzige Hersteller von Gentests für Brustkrebs. Da Tamoxifen auch
      prophylaktisch verabreicht werden kann, stellt es eine wichtige Alternative zur Brustamputation dar, die oft sogar prophylaktisch
      durchgeführt wird. Weil also im Falle einer frühzeitigen Diagnose eine zufriedenstellende medikamentöse Behandlung möglich ist,
      gewinnt der Gentest von Myriad dadurch erheblich an Attraktivität.

      Weiterhin hohes Umsatzwachstum im Bereich der Gentests (z. Z. 25% im Quartal) scheint daher nicht unwahrscheinlich.

      (für weitere Einzelheiten siehe http://biz.yahoo.com/fo/000706/mu2989.html)

      Gruß, ml
      Avatar
      schrieb am 18.07.00 19:51:16
      Beitrag Nr. 12 ()
      Myriad Genetics Awarded U.S. Patent for DNA Sequencing
      - Technology Speeds Gene Discovery and Molecular Diagnostic Testing -
      SALT LAKE CITY, July 18 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN - news) announced today that it has been awarded patent number 6,087,099, entitled, ``Method for Sequencing Both Strands of a Double Stranded DNA in a Single Sequencing Reaction,`` by the United States Patent and Trademark Office.

      The patent covers technology that is instrumental in the acceleration of the DNA sequencing process and in the reduction of its cost. DNA sequencing has become an essential part of genomic and proteomic work such as understanding the makeup of the human genome and developing new, more effective and targeted therapeutic and diagnostic products. The newly patented technology is particularly advantageous when applied to disease gene discovery and the detection of mutations within known genes.

      ``Myriad continues to build upon its record of innovation in its core technologies, allowing the Company to maintain leadership in the proteomic field,`` said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. ``This patented technology is an example of the kind of marked improvement in a core process that permits Myriad to generate higher quality data at lower cost for the Company and its collaborators.``

      The chief inventor of the DNA sequencing technology, Jamila Gupte, commented, ``This method is especially applicable to genetic testing, in which a comparison of both DNA strands is desirable to confirm mutations. Using this technology, the comparison can be done simultaneously, saving significant time and resources. There are additional applications in sequencing regions of chromosomes suspected of holding important genes as well.``

      Myriad Genetics, Inc. is an emerging biopharmaceutical company focused on the development of therapeutic and diagnostic products that are based on the use of genomic and proteomic technologies. The Company has established two wholly owned subsidiaries -- Myriad Pharmaceuticals, Inc., which develops and intends to market therapeutic compounds, and Myriad Genetic Laboratories, Inc., which develops and markets proprietary molecular diagnostic services and has introduced products in the fields of predictive medicine and personalized medicine. The Company has established strategic alliances with Bayer, Eli Lilly, Hitachi, Monsanto, Novartis, Roche, Schering AG and Schering-Plough.

      The discussion in this news release includes forward-looking statements that are subject to certain risks and uncertainties. Such statements are based on management`s current expectations that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements, including, but not limited to, intense competition related to the discovery of disease-related genes; uncertainties as to the extent of future government regulation of the Company`s business, uncertainties as to whether the Company and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutics based on the discovery of disease-related genes and proteins; uncertainties as to the Company`s ability to develop therapeutic lead compounds, which is a new business area for the Company; the risk that markets will not exist for therapeutic lead compounds that the Company develops or if such markets exist, that the Company will not be able to sell compounds, which it develops, at acceptable prices.

      SOURCE: Myriad Genetics, Inc.
      Avatar
      schrieb am 19.07.00 00:52:44
      Beitrag Nr. 13 ()
      @m.lynched+iwa
      Ich befasse mich seit einiger Zeit sehr intensiv mit Myriad Genetics .Die Postings von euch sind interessant, jedoch ist noch einiges hinzuzufügen, das die Sache erst richtig interessant macht:
      1. Das Diagnosesystem von Myriad, BRACAnalysis setzt auf der Welt die Standards für derartige Tests, mit 50% Marktanteil ist Myriad absoluter Weltmarktführer
      2. Die Absatzzahlen werden, wie von Euch bereits erwähnt, in den nächsten Jahren rasant ansteigen.
      3. Ein Test für Darmkrebs steht kurz vor der Einführung
      usw...

      Ihr könnt das Ganze ab nächsten Montag unter www.trading-division.de nachlesen, ich will nicht zu viel verraten... :)

      Gruß Cowboy
      Avatar
      schrieb am 19.07.00 15:09:07
      Beitrag Nr. 14 ()
      schau mal in dein Postfach Cowboy
      Avatar
      schrieb am 20.07.00 15:22:42
      Beitrag Nr. 15 ()
      Company Press Release
      SOURCE: Myriad Genetics, Inc.
      Myriad Genetics, Inc. Names S. George Simon Vice President of Business Development
      SALT LAKE CITY, July 20 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN - news) has named S. George Simon as Vice President of Business Development. Mr. Simon will spearhead the continued expansion of Myriad`s corporate alliances for research and product development.

      Mr. Simon joins Myriad from MorphoGen Pharmaceuticals, Inc., a biopharmaceutical company working in musculoskeletal tissue repair. Mr. Simon held the position of Vice President, Corporate Development, and successfully implemented a progressive business development strategy to drive future growth of the company. Previously, Mr. Simon was Senior Director, Corporate Development for the VivoRx group of companies, which developed biotechnology and biopharmaceutical products in oncology and cell therapy. In addition, Mr. Simon spent over seven years as a consultant to the Canadian Government for the development and commercialization of their biotechnology industry.

      ``We are delighted to have George Simon as Head of Myriad`s business development efforts,`` commented Peter Meldrum, President and Chief Executive Officer of Myriad Genetics. ``His demonstrated ability to both evaluate and represent complex technologies coupled with his experience in biotechnology dealmaking furthers the Company`s ability to leverage its core technologies in the creation of new therapeutic products.``

      Mr. Simon`s group will focus initially on further collaborations using Myriad`s high-speed, automated Protomics technology, ProNet(TM). The ProNet(TM) technologies generate multiple, high-quality drug targets by discovering the biological pathway of a disease-related gene. This technology has already produced over a dozen promising targets in important disease indications for Myriad`s ProNet(TM) collaborators, and well over 100 potential drug targets for evaluation and potential development through Myriad Pharmaceuticals, Inc.

      ``Early on, Myriad identified the need for a powerful proteomics technology and responded with ProNet. The technology has very wide application to therapeutic development and with five major collaborations worth over $170 million to Myriad, has only scratched the surface in terms of the number of possible collaborations it can produce and the value of the technology to pharmaceutical developers. Myriad intends to continue its pioneering work in proteomics and further its leadership role in discovering the important drug targets in the human genome. It is an exciting time to be a part of the success of Myriad,`` commented George Simon, Vice President, Business Development for Myriad Genetics, Inc.

      Myriad Genetics, Inc. is an emerging biopharmaceutical company focused on the development of therapeutic and diagnostic products that are based on the use of genomic and proteomic technologies. The Company has established two wholly owned subsidiaries -- Myriad Pharmaceuticals, Inc., which develops and intends to market therapeutic compounds, and Myriad Genetic Laboratories, Inc., which develops and markets proprietary molecular diagnostic services and has introduced products in the fields of predictive medicine and personalized medicine. The Company has established strategic alliances with Bayer, Eli Lilly, Hitachi, Monsanto, Novartis, Roche, Schering AG and Schering-Plough.

      This and other recent releases are available on Myriad`s Web site at www.myriad.com .

      The discussion in this news release includes forward-looking statements that are subject to certain risks and uncertainties. Such statements are based on management`s current expectations that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements, including, but not limited to, intense competition related to the discovery of disease-related genes; uncertainties as to the extent of future government regulation of the Company`s business, uncertainties as to whether the Company and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutics based on the discovery of disease-related genes and proteins; uncertainties as to the Company`s ability to develop therapeutic lead compounds, which is a new business area for the Company; the risk that markets will not exist for therapeutic lead compounds that the Company develops or if such markets exist, that the Company will not be able to sell compounds, which it develops, at acceptable prices.

      SOURCE: Myriad Genetics, Inc.
      Avatar
      schrieb am 24.07.00 14:30:47
      Beitrag Nr. 16 ()
      Empfehlung: www.myriad.com

      burpy
      Avatar
      schrieb am 16.08.00 18:56:56
      Beitrag Nr. 17 ()
      Myriad Genetics, Inc. Announces 2-for-1 Stock Split
      SALT LAKE CITY, Aug. 16 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN - news) announced today that its Board of Directors has approved a two-for-one stock split of its Common Stock, effected in the form of a stock dividend of one new share for each share of Common Stock outstanding.

      The stock dividend is payable on September 11, 2000 to stockholders of record at the close of business on August 28, 2000. As a result of the stock split, the number of outstanding shares of the Company`s Common Stock will increase to approximately 22,000,000.

      ``The stock split reflects our commitment to our stockholders and expresses our enthusiasm for the Company`s opportunities for continued growth,`` commented Peter D. Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. ``This action is in keeping with the Company`s long-term strategy of broadening our stockholder base and increasing the liquidity of the Company`s shares.``

      Myriad Genetics, Inc. is an emerging biopharmaceutical company focused on the development of therapeutic and diagnostic products that are based on the use of genomic and proteomic technologies. The Company has established two wholly owned subsidiaries. Myriad Pharmaceuticals, Inc. develops and intends to market therapeutic compounds and Myriad Genetic Laboratories, Inc. develops and markets proprietary molecular diagnostic services and has introduced products in the fields of predictive medicine and personalized medicine. The Company has established strategic alliances with Bayer, Eli Lilly, Hitachi, Novartis, Pharmacia, Roche, Schering AG and Schering-Plough.

      The discussion in this news release includes forward-looking statements that are subject to certain risks and uncertainties. Such statements are based on management`s current expectations that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements, including, but not limited to, intense competition related to the discovery of disease-related genes; uncertainties as to the extent of future government regulation of the Company`s business, uncertainties as to whether the Company and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutics based on the discovery of disease-related genes and proteins; uncertainties as to the Company`s ability to develop therapeutic lead compounds, which is a new business area for the Company; the risk that markets will not exist for therapeutic lead compounds that the Company develops or if such markets exist, that the Company will not be able to sell compounds, which it develops, at acceptable prices.

      SOURCE: Myriad Genetics, Inc.
      Avatar
      schrieb am 16.08.00 21:05:44
      Beitrag Nr. 18 ()
      schreibe auch deutsch :D:D:D

      Myriad mit 2:1 Aktiensplit

      Das Biopharma-Unternehmen Myriad Genetics Inc. (Nasdaq: MYGN) meldete heute
      einen Aktiensplit im Verhältnis 2:1. Der Splitt wird in
      Form einer Aktiendividende durchgeführt. Je Anteilsschein erhalten Investoren am
      11. September eine weitere Aktie eingebucht. Der Kurs der
      Aktie halbiert sich somit zu diesem Termin.



      Das Unternehmen
      beschäftigt sich mit vererbten Genmutationen, die das Risiko von
      Krebs, Herzanfällen und anderen Krankheiten erhöhen. Das sogenannte BRACAnalysis-System
      erkennt die Anfälligkeit für Brustkrebs, CardiaRisk dient der Vorhersage
      von möglichen Herz-Kreislauf-Erkrankungen. Mit Bayer, Eli Lilly und Schering-Plough
      bestehen Forschungsallianzen.



      :rolleyes:IWA:rolleyes:
      Avatar
      schrieb am 17.08.00 20:33:09
      Beitrag Nr. 19 ()
      Princeton, New Jersey, Aug. 17 (Bloomberg Data) -- Myriad Genetics Inc. (MYGN US) was reiterated ``buy`` by analyst Alan J. Tuchman at Oscar Gruss & Son Inc.
      Avatar
      schrieb am 18.08.00 02:32:06
      Beitrag Nr. 20 ()
      Myriad to introduce cancer test

      By Ted Griffith, CBS.MarketWatch.com
      Last Update: 5:42 PM ET Aug 17, 2000 NewsWatch
      Latest headlines

      SALT LAKE CITY (CBS.MW) -- Myriad Genetics said Thursday it will introduce a test in September that will identify people who are at high risk of developing colon cancer.



      The test can also help predict a woman`s risk of developing uterine cancer, Myriad Genetics said.

      Myriad (MYGN: news, msgs) said the test, dubbed Colaris, assesses a person`s risk of colon cancer based on the presence of a mutation in genes. The same mutation, the company said, substantially increases a woman`s risk of uterine cancer.

      People who test positive for the mutation have an 80 percent lifetime risk of colon cancer, and women who test positive have a 40 to 60 percent risk of developing uterine cancer, according to the company.

      People identified at risk for cancer can begin a regular schedule of doctor visits to catch the disease early, Myriad said. In many cases, early detection of cancer increases a person`s chances for survival.

      Myriad said it will begin accepting samples for colon and uterine cancer testing nationwide in September. Myriad specializes in developing therapeutic and diagnostic products that are derived from research into genetics and proteins.

      Myriad said its 40-person oncology product sales force will sell the test. The company said worldwide launch of the test will follow introduction in the United States.

      On Wednesday, Myriad said its board has approved a 2-for-1 stock split payable on Sept. 11 to shareholders of record on Aug. 28. The stock of Salt Lake City-based Myriad has risen more than 220 percent since the beginning of the year.


      fazit: :D:D:D:D:D:D:D:D:D:D
      Avatar
      schrieb am 18.08.00 18:00:27
      Beitrag Nr. 21 ()
      Liebe Myriadisten,

      wann werden die Quartalszahlen bekanntgegeben?

      Weiß einer was Näheres?

      Vielen Dank,

      Geboren1971
      Avatar
      schrieb am 18.08.00 18:32:23
      Beitrag Nr. 22 ()
      Kann mir jemand sagen warum die so fällt?

      Vielen Dank

      Frey-pop
      Avatar
      schrieb am 19.08.00 01:11:13
      Beitrag Nr. 23 ()
      Würde ich auch gerne wissen, oder liegts an der Rede vom Gore,oder sind die abgesprungen die sich mehr von der Bekanntgabe des Split erwartet haben, oder es sind die ausgestiegen die bereits von dem Split wußten, oder,oder,oder

      Wünsche ein schönes WE
      Avatar
      schrieb am 20.08.00 10:21:16
      Beitrag Nr. 24 ()
      Könnte der Fall der Aktie damit zu tun haben?!?



      MYRIAD GENETICS, INC.

      NOTICE OF SPECIAL MEETING OF STOCKHOLDERS

      To Be Held August 15, 2000
      To the Stockholders of Myriad Genetics, Inc.:

      NOTICE IS HEREBY GIVEN that a Special Meeting of Myriad Genetics, Inc., a Delaware corporation (the "Company"), will be held on Tuesday, August 15, 2000, at the offices of Myriad Genetics, Inc., 320 Wakara Way, Salt Lake City, Utah, at 9:00 a.m. for the following purposes:

      1. To consider and take action upon a proposal recommended by the Board of Directors to amend the Company`s Restated Certificate of Incorporation to increase the Company`s authorized common stock from 15 million shares to 60 million shares.

      2. To transact such other business as may be properly brought before the Special Meeting and any adjournments thereof.

      The Board of Directors has fixed the close of business on July 17, 2000 as the record date for the determination of stockholders entitled to notice of and to vote at the Special Meeting and at any adjournments thereof.

      All stockholders are cordially invited to attend the Special Meeting. Whether you plan to attend the Special Meeting or not, you are requested to complete, sign, date and return the enclosed proxy card as soon as possible in accordance with the instructions on the proxy card. A pre-addressed, postage prepaid return envelope is enclosed for your convenience.


      BY ORDER OF THE BOARD OF DIRECTORS


      /s/ Christopher L. Wight

      Christopher L. Wight
      Secretary





      July 27, 2000



      --------------------------------------------------------------------------------

      MYRIAD GENETICS, INC.
      320 WAKARA WAY
      SALT LAKE CITY, UTAH 84108
      (801) 584-3600


      --------------------------------------------------------------------------------


      PROXY STATEMENT


      --------------------------------------------------------------------------------


      GENERAL INFORMATION
      This Proxy Statement is furnished in connection with the solicitation by the Board of Directors of Myriad Genetics, Inc., a Delaware corporation (the "Company"), of proxies, in the accompanying form, to be used at the Special Meeting of Stockholders to be held at the offices of Myriad Genetics, Inc., 320 Wakara Way, Salt Lake City, Utah, on Tuesday, August 15, 2000, at 9:00 a.m., and any adjournments thereof (the "Meeting").

      Where the stockholder specifies a choice on the enclosed proxy card as to how his or her shares are to be voted on a particular matter, the shares will be voted accordingly. If no choice is specified, the shares will be voted FOR the proposal to amend the Company`s Restated Certificate of Incorporation. Any proxy given pursuant to this solicitation may be revoked by the person giving it at any time before its use by delivering to the Company a written notice of revocation or a duly executed proxy bearing a later date. Any stockholder who has executed a proxy but is present at the Meeting, and who wishes to vote in person, may do so by revoking his or her proxy as described in the preceding sentence. Shares represented by valid proxies in the form enclosed, received in time for use at the Meeting and not revoked at or prior to the Meeting, will be voted at the Meeting. The presence, in person or by proxy, of the holders of a majority of the outstanding shares of the Company`s common stock, par value $.01 per share ("Common Stock"), is necessary to constitute a quorum at the Meeting.

      The affirmative vote of a majority of the outstanding shares of Common Stock is required to approve the proposal to amend the Company`s Restated Certificate of Incorporation. Abstentions and broker non-votes will have the same effect as a vote against the proposal.

      The close of business on July 17, 2000 has been fixed as the record date for determining the stockholders entitled to notice of and to vote at the Meeting. As of the close of business on July 17, the Company had 10,935,353 shares of Common Stock outstanding and entitled to vote. Holders of Common Stock are entitled to one vote per share on all matters to be voted on by stockholders.

      The cost of soliciting proxies, including expenses in connection with preparing and mailing this Proxy Statement, will be borne by the Company. In addition, the Company will reimburse brokerage firms and other persons representing beneficial owners of Common Stock of the Company for their expenses in forwarding proxy material to such beneficial owners. Solicitation of proxies by mail may be supplemented by telephone, telegram, telex and personal solicitation by the directors, officers or employees of the Company. No additional compensation will be paid for such solicitation.

      This Proxy Statement and the accompanying proxy are being mailed on or about July 27, 2000 to all stockholders entitled to notice of and to vote at the Meeting.



      --------------------------------------------------------------------------------

      PRINCIPAL STOCKHOLDERS
      The following table sets forth certain information known to the Company with respect to the beneficial ownership of Common Stock as of June 30, 2000 by: (i) all persons known to the Company to be beneficial owners of five percent (5%) or more of Common Stock, (ii) each of the Company`s directors, (iii) each of the Company`s executive officers, and (iv) all of the Company`s directors and executive officers as a group. The number of shares beneficially owned by each director or executive officer is determined under the rules of the Securities and Exchange Commission and the information is not necessarily indicative of beneficial ownership for any other purpose. Shares of Common Stock subject to convertible securities that are currently exercisable or convertible or which will become exercisable or convertible within 60 days of June 30, 2000 are deemed to be beneficially owned by the person holding such options for computing the percentage ownership of such person, but are not treated as outstanding for computing the percentage of any other person. Except as otherwise indicated, the Company believes that the beneficial owners of Common Stock listed below, based upon such information furnished by such owners, have sole voting and investment power with respect to such shares, subject to community property laws where applicable.




      Number of Shares Percentage of Shares
      Beneficially Owned (1) Beneficially Owned (1)(2)
      Beneficial Owner ---------------------- -------------------------
      Peter Friedli (3)............ 663,750 6.1%
      Friedli Corporate Finance AG
      Freigutstrasse 5
      8002 Zurich, Switzerland

      FMR Corp. (4)................ 596,500 5.5%
      82 Devonshire St.
      Boston, MA 02109

      Wanger Asset Mgt............. 583,000 5.3%
      227 W. Monroe St.
      Chicago, IL 60606

      Mark H. Skolnick, Ph.D. (5).. 440,106 4.0%

      Peter D. Meldrum (6)......... 168,016 1.5%

      Walter Gilbert, Ph.D. (7).... 115,970 1.1%

      John J. Horan (8)............ 75,714 *

      Arthur H. Hayes, M.D. (8).... 45,000 *

      Jay M. Moyes (9)............. 39,901 *

      Gregory C. Critchfield M.D.
      (8)......................... 23,000 *

      Christopher L. Wight (10).... 21,400 *

      Adrian N. Hobden Ph.D. (11).. 18,000 *

      Arnold Oliphant (8).......... 11,137 *

      Dale A. Stringfellow, Ph.D.
      (8)......................... 10,371 *

      George S. Simon.............. 0 --

      Alan J. Main, Ph.D........... 0 --

      Michael J. Berendt, Ph.D..... 0 --

      Linda S. Wilson, Ph.D........ 0 --

      All executive officers and
      directors as a group (15
      persons) (12)............... 968,615 8.5%





      --------------------------------------------------------------------------------

      * Less than one percent.

      2

      --------------------------------------------------------------------------------
      (1) Percentage of beneficial ownership is calculated assuming 10,933,241 shares of Common Stock were outstanding as of June 30, 2000. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities.
      (2) This table is based upon information supplied to the Company by executive officers, directors and principal stockholders. The address of each officer and director identified in this table is that of the Company`s executive offices, 320 Wakara Way, Salt Lake City, Utah 84108.
      (3) Includes shares held by Inventure, Inc., Joyce, Ltd., Pine, Inc., and Spring Technology Corp., in each of which Mr. Friedli has a controlling interest. Also includes a currently exercisable warrant to purchase 32,750 shares of Common Stock.
      (4) This information is based solely on a Schedule 13F filed on May 15, 2000 with the Securities and Exchange Commission for the quarter ended March 31, 2000.
      (5) Includes shares held directly by Dr. Skolnick and his wife, shares held by a family limited partnership of which Dr. Skolnick is a general partner, as well as shares held by certain family members. Also includes 165,371 shares of Common Stock subject to currently exercisable options.
      (6) Includes 16,848 shares of Common Stock subject to currently exercisable options.
      (7) Includes 46,485 shares of Common Stock owned by Dr. Gilbert`s wife, as to which Dr. Gilbert disclaims beneficial ownership. Also includes 43,000 shares of Common Stock subject to currently exercisable options.
      (8) Consists of shares of Common Stock subject to currently exercisable options.
      (9) Includes shares held directly by Mr. Moyes and his children. Also includes 37,743 shares of Common Stock subject to currently exercisable options.
      (10) Includes 11,400 shares of Common Stock subject to currently exercisable options.
      (11) Includes 10,000 shares of Common Stock subject to currently exercisable options.
      (12) Includes 449,584 shares of Common Stock subject to currently exercisable options.
      To the Company`s knowledge, each beneficial owner of more than 10% of Common Stock filed all reports and reported all transactions on a timely basis with the Securities and Exchange Commission, the National Association of Securities Dealers, Inc. and the Company.


      PROPOSAL TO INCREASE AUTHORIZED COMMON STOCK
      The Board of Directors of the Company has approved and recommends that the stockholders approve an amendment to the Company`s Restated Certificate of Incorporation to increase the authorized shares of Common Stock from 15 million shares to 60 million shares. The proposed amendment amends and restates the first sentence of Article FOURTH, Section A of the Company`s Restated Certificate of Incorporation to read in its entirety as follows:

      The total number of shares of capital stock of all classes which the Corporation is authorized to issue is 65,000,000, of which shares 60,000,000 of the par value of $.01 each shall be designated "Common Stock", and of which shares 5,000,000 of the par value of $.01 each shall be a class designated "Preferred Stock".

      If the proposed amendment is adopted and the authorized number of shares of Common Stock is increased, then the additional authorized shares of Common Stock may be issued from time to time by action of the Board of Directors, without further stockholder approval, for such consideration as the Board of Directors determines to be adequate, or without consideration as a stock dividend or stock split. Stockholders have no preemptive rights to purchase or subscribe for any additional shares of Common Stock.

      On June 30, 2000, the Company had 10,933,241 shares of Common Stock issued and outstanding. Also on that date, the Company had 1,881,447 shares of Common Stock subject to outstanding options. Accordingly, a high percentage of the Company`s 15 million authorized shares have been issued or reserved for issuance and thus relatively few shares are available to the Company for use in connection with its future financing and other corporate needs.


      3

      --------------------------------------------------------------------------------
      The Board of Directors of the Company believes the increase in the authorized shares is necessary to provide the Company with the flexibility to act in the future with respect to financing programs, acquisitions, stock splits, stock dividends, and other corporate purposes without the delay and expense incidental to obtaining stockholder approval each time an opportunity requiring the issuance of shares may arise.
      The additional shares of Common Stock to be authorized by adoption of the amendment to the Restated Certificate of Incorporation would have rights identical to the currently outstanding shares of Common Stock. Adoption of the proposed amendment to the Restated Certificate of Incorporation would not affect the rights of the holders of currently outstanding shares of Common Stock. Any issuance of shares of Common Stock authorized by the proposed amendment would have the normal consequences associated with increasing the number of shares outstanding, including dilution of share ownership, voting rights and earnings per share.

      Adoption of the amendment to the Restated Certificate of Incorporation to increase the Company`s authorized Common Stock requires the vote of a majority of the outstanding shares of Common Stock. If the proposal is approved, the Company intends to file a certificate of amendment to the Company`s Restated Certificate of Incorporation shortly after the Meeting although it will not be required to do so. The Board of Directors may abandon the amendment without any further action by the stockholders at any time prior to the filing of the certificate of amendment. The amendment to the Restated Certificate of Incorporation will be effective immediately upon acceptance of filing by the Secretary of State of Delaware.

      THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THIS PROPOSAL.


      OTHER ACTION
      Management is not aware at this time of any other matters that will be presented for action at the Meeting. Should any such matters be presented, the proxies grant power to the proxy holders to vote shares represented by the proxies in the discretion of such proxy holders.


      STOCKHOLDER PROPOSALS
      The deadline for submitting proposals to be considered for inclusion in the proxy statement relating to the Annual Meeting of Stockholders to be held in 2000 has passed. Stockholder proposals may still be submitted to be considered for presentation at such meeting, although not included in the proxy statement. Such stockholder proposals must be received, marked for the attention of:
      Secretary, Myriad Genetics, Inc., 320 Wakara Way, Salt Lake City, Utah 84108, no later than September 11, 2000 and no earlier than August 11, 2000.

      WHETHER OR NOT YOU INTEND TO BE PRESENT AT THE MEETING, YOU ARE URGED TO FILL OUT, SIGN, DATE AND RETURN THE ENCLOSED PROXY AT YOUR EARLIEST CONVENIENCE.


      BY ORDER OF THE BOARD OF DIRECTORS


      /s/ Christopher L. Wight

      Christopher L. Wight
      Secretary





      July 27, 2000


      4

      --------------------------------------------------------------------------------

      Appendix

      MYRIAD GENETICS, INC.

      THIS PROXY IS BEING SOLICITED BY MYRIAD GENETICS, INC.`S
      BOARD OF DIRECTORS
      The undersigned, revoking any previous proxies relating to these shares, hereby acknowledges receipt of the Notice and Proxy Statement dated July 27, 2000 in connection with the Special Meeting to be held at 9:00 a.m. on Tuesday, August 15, 2000 at the offices of Myriad Genetics, Inc., 320 Wakara Way, Salt Lake City, Utah and hereby appoints Peter D. Meldrum and Jay M. Moyes, and each of them (with full power to act alone), the attorneys and proxies of the undersigned, with power of substitution to each, to vote all shares of the Common Stock of MYRIAD GENETICS, INC. registered in the name provided herein which the undersigned is entitled to vote at the Special Meeting of Stockholders, and at any adjournments thereof, with all the powers the undersigned would have if personally present. Without limiting the general authorization hereby given, said proxies are, and each of them is, instructed to vote or act as follows on the proposal set forth in said Proxy.

      This Proxy when executed will be voted in the manner directed herein. If no direction is made this Proxy will be voted FOR the proposal to amend the Company`s Restated Certificate of Incorporation.

      In their discretion the proxies are authorized to vote upon such other matters as may properly come before the meeting or any adjournments thereof.

      SEE REVERSE SIDE FOR PROPOSAL. If you wish to vote in accordance with the Board of Directors` recommendation, just sign on the reverse side. You need not mark any boxes.


      (SEE REVERSE SIDE)



      X Please mark votes as in this example.


      --------------------------------------------------------------------------------

      1. Proposal to amend the Restated Certificate of Incorporation of Myriad Genetics, Inc. to increase the authorized shares of Common Stock from 15 million shares to 60 million shares.


      __ FOR __ AGAINST __ ABSTAIN



      Please sign exactly as name(s)
      appears hereon. Joint owners should
      each sign. When signing as attorney,
      executor, administrator, trustee or
      guardian, please give full title as
      such.

      Signature:__________________________
      Date:_______________________________

      Signature:__________________________
      Date:_______________________________








      --------------------------------------------------------------------------------
      End of Filing

      © 2000 | Financial Insight Systems, Inc.
      Avatar
      schrieb am 20.08.00 14:40:20
      Beitrag Nr. 25 ()
      nochmals z.Kenntnis (in deutsch)

      Myriad gab den Start eines neuen vorbeugenden Krebstests bekannt.


      Der Colaris™ Krebstest soll die Veranlagung zu bestimmten Formen von Darmkrebs und
      Gebährmutterhalskrebs bestimmen. Die auf Mutationen überprüften Gene erhöhen außerdem
      maßgeblich das Risiko für Gebährmutterschleimhautkrebs. Der Colaris Test ist der dritte
      molekulardiagnostik Test, der Myriads DNA Sequenzing Plattform nutzt. Die Einführung des Tests
      ist für September geplant.

      Auf bald wieder steigenden Kurs !!!!!!!!!!!!!

      gruß maha
      Avatar
      schrieb am 22.08.00 20:58:19
      Beitrag Nr. 26 ()
      Myriad Genetics Reports
      By Tom Jacobs

      Emerging biopharmaceutical company Myriad Genetics (Nasdaq: MYGN - news) reported increased revenues and reduced losses for the year ending June 30, 2000. Year-over-year revenues jumped 34% from $25.3 million to $34.0 million, due to growth in Myriad`s medical diagnostics and research revenues. The company`s losses narrowed from $1.06 per share in fiscal 1999 to $0.86 per share in 2000.

      Myriad conducts drug discovery and development using genomics and proteomics tools. Investors jumped on these buzzwords in 2000 and tripled Myriad`s market cap to $1.4 billion since December. But is a self-described "emerging" biotech drug company worth those big bucks, when biotech IPOs have given us a bevy of research-stage product-less hopefuls sporting market caps of $50 million?

      To answer, let`s squirrel behind Myriad`s press release. Armed with the Fool`s Biotechnology Crash Course, I`m taking a critical look at the company`s list of accomplishments, sorting them from "so what?" to "hmm... very interesting":

      "Discovery of an exciting diabetes gene that may lead to therapeutic and predictive medicine products for diabetes."
      Wow, a gene! It "may" lead to something! Too bad it only faces a few years of looking for a drug candidate, then 15 years and $500 million before it hits the market. Who`s bellying up with the cash?
      "Discovery of promising drug targets in the AIDS and rheumatoid arthritis fields. The HIV targets represent a new class of therapeutics and a novel approach to halting viral replication that may also be applicable to additional viral diseases."
      How "promising"? What stage are the targets in? How many years from human tests?
      "Discovery of a colon cancer drug compound, designated MPI-42511, which selectively kills colon cancer cells, the program is being advanced toward human clinical trials."
      OK, "being advanced toward" beats "may" and "promising." Where is the drug in the 6.5-year preclinical testing phase? Remember that even when a drug candidate enters human clinical trials, it will endure an average of 8.5 years of FDA review and approval -- if it`s successful -- before hitting the market.
      "Discovery of an important prostate cancer gene. The discovery triggered a $1 million milestone payment from strategic partner Schering-Plough (NYSE: SGP - news)."
      Though this is only discovery of the gene, it`s a big enough deal to generate cash. Investors in emerging biotech drug companies like to see cash-rich pharmas paying for discoveries and floating the company while it fills its drug pipeline. One million bucks is a start. What are the other milestones? Remember, it takes 15 years and $500 million to run the drug-approval gauntlet.
      "Delivery of five new validated drug targets to corporate partners."
      Good. It sounds like the partners pay for those targets, just as Schering-Plough kicked in some real money for the gene discovery. But how much did the partners pay for the five new targets, and what rights did Myriad sign away? Savvy companies like Millennium Pharmaceuticals (Nasdaq: MLNM - news) have struck some great deals that allow it to retain key development rights to targets.
      "Development of four strategic alliances totaling $86 million in potential value to Myriad, with partners Hitachi, Novartis, Pharmacia and Roche."
      "Potential" value. I like that. Kind of like your employer saying, "Your salary represents potential payments." But this is intriguing enough to merit further research.
      When you`ve found a biotech worth further investigation, check out the company`s website; does it tell you more about the company`s deals? Review the latest 10-K and 10-Q, then ask yourself the following questions:


      How much money does the company have?

      Will the company go out of business before it sells a drug

      How much will the company dilute my shares when it issues more in exchange for future cash?

      When the company needs more money, will anyone provide it?

      Too many research-stage companies with no products in the pipeline and tenuous alliances with the big pharmas call themselves "biopharmaceutical companies," leaving out key words such as "emerging" or even "dreaming." Myriad tells you where it stands. Foolish investors can begin there and check what`s under the microscope.
      Avatar
      schrieb am 22.08.00 22:26:17
      Beitrag Nr. 27 ()
      in Teutsch :D

      Myriad Genetics verringert Verluste

      Das Biotechunternehmen Myriad Genetics (Nasdaq: MYGN) konnte im letzten
      Fiskaljahr, das am 30. Juni 2000 endete, die Umsätze
      leicht erhöhen und den Verlust mindern. Die Umsätze stiegen
      um 34 Prozent auf 34 Mio. US-Dollar, getrieben durch
      das Wachstum in Myriads medizinischer Diagnostik und durch erhöhte
      Forschungseinnahmen. Die Verluste konnten von 1,06 Dollar je Aktie
      auf 86 Cents gesenkt werden.



      Die Forschungsausgaben stiegen um 20
      Prozent auf 28,1 Mio. US-Dollar. Dies spiegelt die Anstrengungen
      des Unternehmens wieder die Medikamentforschung und -entwicklung durch die
      Tochter Myriad Pharmaceuticals weiter zu verstärken.

      Das Unternehmen beschäftigt
      sich mit vererbten Genmutationen, die das Risiko von Krebs,
      Herzanfällen und anderen Krankheiten erhöhen. Das sogenannte BRACAnalysis-System erkennt
      die Anfälligkeit für Brustkrebs, CardiaRisk dient der Vorhersage von
      möglichen Herz-Kreislauf-Erkrankungen. Mit Bayer, Eli Lilly und Schering-Plough bestehen
      Forschungsallianzen.
      Avatar
      schrieb am 24.08.00 00:25:04
      Beitrag Nr. 28 ()
      I did go, but since it was a special meeting, not much was really discussed. Will try to go again in November.
      The increase in shares was approved and Pete discussed that there will not be dilution of stock and that they wanted the share price to be affordable to individual investors so they could buy round lots of 100 shares easily.
      Pete pointed out that MYGN has applied for 230 patents this year and the goal is one a day to get to about 360.
      The meeting was only about 30 minutes. Pete did sound upbeat and tired at the same time. It appeard that he was very busy.
      The facilities are impressive and I looked into every room I could on the way through the building. All I saw was labs, labs and more labs which I really liked being a microbiologist myself.
      MYGN is staffed by youthful people who all looked smart and very busy.
      Overall, I was impressed and look forward to the larger November meeting.
      Hopefully we`ll get an announcement for a 4 for 1 split shortly.


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.

      Investoren beobachten auch:

      WertpapierPerf. %
      -0,69
      +11,83
      +0,33
      -0,30
      -0,26
      -0,33
      +0,06
      +0,17
      +1,95
      +0,66
      22.03.24 · globenewswire · Myriad Genetics
      20.03.24 · globenewswire · Myriad Genetics
      04.03.24 · wO Chartvergleich · Myriad Genetics
      27.02.24 · globenewswire · Myriad Genetics
      27.02.24 · globenewswire · Myriad Genetics
      21.02.24 · globenewswire · Myriad Genetics
      15.02.24 · globenewswire · Myriad Genetics
      01.02.24 · globenewswire · Myriad Genetics
      30.01.24 · globenewswire · Myriad Genetics
      19.01.24 · globenewswire · Myriad Genetics
      MYRIAD +++ Eine interessante Aktie im Schatten der großen und gepuschten+++